Drug intelligence / Profile preview

SRD-005

Development stage: Preclinical
Lead developer: Sardocor
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Inhalation

Overview

SRD-005 is an inhalation formulation gene therapy under preclinical development by Sardocor, a subsidiary of Medera. It is being investigated for the treatment of pulmonary fibrosis. The drug's mechanism of action involves gene transference, aiming to deliver genetic material via inhalation to address the underlying causes of the disease in the lungs.

Beyond the preview

Go deeper on SRD-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRD-005.

Explore the full profile